LUNG CANCER TREATMENT:
PRECISION ONCOLOGY IN CHINA

Lung cancer is not one disease. Molecular subtype — defined by driver mutation or fusion gene — determines treatment more than histology alone. A KRAS G12C adenocarcinoma and an EGFR-mutated adenocarcinoma look identical under the microscope but require completely different treatment.

“Treating lung cancer without molecular testing is, at best, suboptimal — and at worst, denying the patient their most effective option.”

• Adenocarcinoma (40% of all lung cancer)

  Most common NSCLC subtype. Arises peripherally; most common in never-smokers. Highest frequency of actionable driver mutations — EGFR, ALK, ROS1, KRAS, RET, MET, HER2, NTRK. Comprehensive NGS is most critical for this subtype.

• Squamous Cell Carcinoma (25%)

  Arises centrally from major airways. More strongly smoking-associated. Driver mutations at lower frequency; FGFR1 amplification and PDL1 high expression relevant in subsets. KEYNOTE-407: pembrolizumab + chemo is standard first-line.

• Small Cell Lung Cancer — SCLC (15%)

  Biologically distinct: neuroendocrine differentiation, extremely rapid proliferation, near-universal TP53/RB1 loss, no EGFR/ALK mutations. Exquisitely chemosensitive initially but almost universally recurs. Staged as limited vs extensive — not TNM.

• Non-Smoker Lung Cancer in Asia

  In China, 30–40% of all lung cancer occurs in never-smokers. In Chinese women, up to 60–70%. Cooking fume exposure, indoor/outdoor air pollution, and genetic susceptibility drive EGFR mutations. This population carries the highest rates of targetable driver alterations globally.

Starting treatment without comprehensive molecular testing is a clinical error. Every advanced NSCLC patient must have a full NGS panel — not sequential single-gene tests — before first-line treatment is chosen.

• EGFR Mutation (exon 19 del / exon 21 L858R / exon 20 ins)

  Sensitising mutations (ex19del, L858R) predict TKI response. Exon 20 insertions predict amivantamab response. T790M tested at first-gen TKI progression. Mandatory for all non-squamous NSCLC — and for squamous if never-smoker or mixed histology.

• ALK Fusion / ROS1 Fusion

  ALK: 3–5% of NSCLC; more common in younger never-smokers. ROS1: 1–2%. Both detected by FISH, IHC, or NGS. ALK-rearranged: lorlatinib, alectinib, or brigatinib. ROS1-rearranged: entrectinib (preferred for CNS) or crizotinib.

• KRAS G12C / RET Fusion / MET Exon 14 Skip

  KRAS G12C (~13% Western, lower in Asian): sotorasib or adagrasib. RET fusion (1–2%): selpercatinib or pralsetinib (85% ORR). MET ex14 skip (3–4%): capmatinib or tepotinib. All require NGS for detection.

• BRAF V600E / HER2 Mutation / NTRK Fusion

  BRAF V600E (2–3%): dabrafenib + trametinib (64% ORR). HER2 activating mutation (2–3%, predominant in Asian never-smoker women): trastuzumab deruxtecan (T-DXd). NTRK fusion (<1%): larotrectinib or entrectinib (tumour-agnostic).

• PD-L1 TPS (22C3 assay)

  Mandatory for all advanced NSCLC regardless of histology. TPS ≥50%: pembrolizumab monotherapy (KEYNOTE-024). TPS 1–49% or negative: pembrolizumab + platinum chemo (KEYNOTE-189/407). Do not use immunotherapy monotherapy in EGFR/ALK-positive patients.

• NGS Panel vs Sequential Testing

  Comprehensive NGS simultaneously evaluates all targets from one tissue sample — preserving limited biopsy material, reducing time to treatment. Chinese genomics labs (BGI, Burning Rock, Genetron, WuXi) offer validated lung cancer panels at substantially lower cost than Western platforms. CancerFax can facilitate testing.

EGFR TKI treatment has evolved through three generations over 20 years. Osimertinib (3rd gen) is now the standard first-line treatment globally — and Chinese oncologists have the world's deepest experience managing EGFR mutations, resistance, and subsequent lines.

Every advanced NSCLC patient deserves a complete driver mutation evaluation. Each positive result unlocks a specific targeted therapy with substantially better outcomes than chemotherapy alone.

Treatment strategy is determined by the combination of stage AND molecular profile. Molecular testing results must be available before any first-line decision is made in advanced disease.

1. 1

   Stage I–II: Surgery First

   VATS or robotic lobectomy (preferred over open thoracotomy). Segmentectomy for tumours ≤2cm peripheral (JCOG0802: non-inferior OS). Adjuvant chemo for Stage II+. EGFR-mutated Stage IB–IIIA: adjuvant osimertinib 3 years (ADAURA: HR 0.20). PD-L1 ≥1% Stage II–IIIA: adjuvant atezolizumab (IMpower010) after chemo.

2. 2

   Stage I–II (Medically Inoperable): SBRT

   Stereotactic body radiotherapy (SBRT/SABR): 48–60 Gy in 3–5 fractions. 3-year local control >90% for peripheral tumours — comparable to surgical outcomes. Increasingly offered as patient-choice alternative to surgery for operable Stage I peripheral tumours.

3. 3

   Stage III Unresectable: Concurrent CRT + Durvalumab (PACIFIC)

   Concurrent platinum-based chemoradiation (60–66 Gy, 6–7 weeks) followed by 12 months durvalumab consolidation. PACIFIC trial: mPFS 17.2 vs 5.6m; OS not reached at 4yr vs 29.1m placebo. Standard of care for unresectable Stage III. PD-L1 testing and EGFR testing required before durvalumab.

4. 4

   Stage III Resectable: Neoadjuvant Chemo-Immunotherapy + Surgery

   CHECKMATE 816 (nivolumab + chemo): pathological CR 24% vs 2.2% with chemo alone. For resectable Stage IIIA with limited N2 involvement. EGFR/ALK status must be known before immunotherapy use — driver-positive patients generally do not benefit from immunotherapy.

5. 5

   Stage IV: Molecular Profile Drives All Decisions

   Driver mutation present → appropriate TKI (osimertinib, lorlatinib, selpercatinib, etc.). No driver mutation + PD-L1 ≥50% → pembrolizumab monotherapy. No driver mutation + PD-L1 <50% → pembrolizumab + platinum doublet. Comprehensive NGS mandatory before any first-line choice.

Pembrolizumab and durvalumab have transformed outcomes for driver-negative NSCLC and Stage III disease. Understanding the specific trial populations helps match the right immunotherapy to the right patient.

VATS lobectomy is now the standard surgical approach at high-volume thoracic centres. Robotic-assisted thoracic surgery (RATS) is growing. Both offer equivalent oncological outcomes to open thoracotomy with substantially better recovery.

Radiation has three distinct roles in lung cancer: curative SBRT for early-stage inoperable disease, definitive concurrent chemoradiation for Stage III, and palliative radiation for symptom control in advanced disease.

• SBRT / SABR — Early Stage (Curative)

  48–60 Gy in 3–5 fractions with daily image guidance and respiratory motion management. 3-year local control >90% for peripheral Stage I–II tumours — comparable to surgery. Standard for medically inoperable patients; increasingly patient-choice for operable small peripheral tumours. Central tumours require modified dose schedules.

• Concurrent Chemoradiation — Stage III (PACIFIC Regimen)

  Platinum-based chemo concurrent with 60–66 Gy IMRT/VMAT over 6–7 weeks, followed by 12 months durvalumab. Mean lung dose and V20 (lung volume receiving ≥20 Gy) are key toxicity predictors for radiation pneumonitis. Proton beam reduces cardiac/pulmonary dose where available.

• SRS for Brain Metastases

  Stereotactic radiosurgery achieves 85–95% 1-year local control per metastasis while avoiding whole-brain radiation toxicity (cognitive decline, hair loss). Standard for 1–5 brain metastases. For EGFR/ALK-positive patients, osimertinib or lorlatinib CNS activity may reduce or defer brain radiation.

• Palliative Radiation

  Short regimens (8 Gy single fraction; 20 Gy/5 fractions) effectively palliate haemoptysis, SVC obstruction, bone pain, endobronchial obstruction. SBRT for oligometastatic disease (1–5 sites) may extend PFS. Spinal cord compression: emergency radiation or surgical decompression.

SCLC is biologically and clinically distinct from NSCLC — no EGFR/ALK mutations, no targeted therapy options, treated entirely with chemotherapy and immunotherapy. Stage at presentation is the primary treatment determinant.

China bears the world's largest lung cancer burden — 800,000+ new cases/year — and has developed unmatched clinical expertise, particularly in EGFR-mutated NSCLC where over 200,000 cases per year are treated at Chinese academic centres.

“For international patients from South Asia, Southeast Asia, and the Middle East who carry EGFR mutations, China is uniquely positioned as the world's most expert and cost-effective treatment destination.”

• Why China Leads in EGFR

  200,000+ EGFR-mutated NSCLC cases per year. Chinese centres co-ran the IPASS trial (2009, first EGFR TKI approval), FLAURA, and FLAURA2. Deep practical expertise in TKI resistance mechanisms, liquid biopsy interpretation, and subsequent line strategies that is unmatched globally.

• Leading Chinese Lung Cancer Centres

  National Cancer Centre CAMS (Beijing) — flagship programme, international trials. Shanghai Chest Hospital — China's most specialised lung hospital; highest VATS/robotic volume. Peking University Cancer Hospital — EGFR and immunotherapy expertise. Sun Yat-sen University Cancer Centre (Guangzhou) — top choice for Southeast Asian patients.

• EGFR TKI Cost Advantage

  Osimertinib on China's NRDL (National Reimbursement Drug List) — substantially more affordable than in most countries. Domestic generics further reduce cost. Full TKI panel (gefitinib, erlotinib, afatinib, osimertinib) available at controlled prices. Comprehensive NGS testing via Burning Rock, BGI, Genetron at a fraction of Western lab costs.

• CancerFax Lung Cancer Navigation

  CancerFax reviews histology, molecular testing, and prior treatment history; facilitates comprehensive NGS if incomplete; identifies the right Chinese thoracic oncologist for each molecular profile; coordinates second opinions, clinical trial enrolment (especially for resistance mechanisms), visa and logistics, and post-treatment handover.

• 30–50%EGFR Mutation Rate in Asian NSCLCvs 10–15% in Western populations. Chinese oncologists treat 200,000+ EGFR-mutated patients per year.
• 38.6mMedian OS with Osimertinib (FLAURA)vs 31.8 months with 1st-gen TKIs. Plus superior CNS control and better tolerability.
• HR 0.20Adjuvant Osimertinib Recurrence Reduction (ADAURA)80% reduction in disease-free survival events for Stage IB–IIIA EGFR-mutated NSCLC post-surgery.
• >90%3-Year Local Control with SBRTFor peripheral Stage I–II NSCLC — comparable to surgical resection in operable patients.

Frequently Asked Questions